Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are VSTM, ADMA, EOLS, ZVRA, NKTR, and represent 45.84% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: VSTM (+$11M), EOLS, XFOR, OABI, ABEO, NKTR, EDSA, SLNO, DAWN, LUNG.
- Started 19 new stock positions in LRMR, EDSA, JSPR, CMMB, OABI, HSDT, PCSA, CTMX, PLRX, AQST. CDXS, WHWK, XFOR, SLNO, GOSS, MNKD, MXCT, RARE, ABVX.
- Reduced shares in these 10 stocks: INDV (-$6.0M), ENTA, Iteos Therapeutics, ANIP, ANIK, ARDX, RZLT, XOMA, Y Mabs Therapeutics, COLL.
- Sold out of its positions in ANIP, ACHV, ANIK, CHRS, COLL, CLYM, CALC, Hillevax, Iteos Therapeutics, KALV. KURA, LQDA, GLUE, MYO, NUVB, SPRO, Theratechnologies, XERS, Y Mabs Therapeutics.
- Stonepine Capital Management was a net buyer of stock by $6.4M.
- Stonepine Capital Management has $123M in assets under management (AUM), dropping by 20.68%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 58 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Verastem Com New (VSTM) | 19.2 | $24M | +82% | 2.7M | 8.83 |
|
| Adma Biologics (ADMA) | 8.8 | $11M | 739k | 14.66 |
|
|
| Evolus (EOLS) | 7.7 | $9.4M | +67% | 1.5M | 6.14 |
|
| Zevra Therapeutics Com New (ZVRA) | 6.3 | $7.7M | +4% | 810k | 9.51 |
|
| Nektar Therapeutics Com New (NKTR) | 3.9 | $4.8M | +69% | 85k | 56.90 |
|
| Day One Biopharmaceuticals I (DAWN) | 3.7 | $4.6M | +43% | 647k | 7.05 |
|
| Xoma Royalty Corporation Com New (XOMA) | 3.6 | $4.4M | -24% | 116k | 38.54 |
|
| ACADIA Pharmaceuticals (ACAD) | 3.0 | $3.7M | -22% | 175k | 21.34 |
|
| Enanta Pharmaceuticals (ENTA) | 3.0 | $3.7M | -49% | 305k | 11.97 |
|
| X4 Pharmaceuticals Com New (XFOR) | 2.9 | $3.6M | NEW | 1.1M | 3.42 |
|
| Omniab (OABI) | 2.8 | $3.4M | NEW | 2.1M | 1.60 |
|
| Surrozen Com New (SRZN) | 2.6 | $3.2M | -18% | 250k | 12.88 |
|
| Tela Bio (TELA) | 2.6 | $3.2M | +3% | 2.2M | 1.49 |
|
| Indivior Ord (INDV) | 2.0 | $2.4M | -71% | 100k | 24.11 |
|
| Abeona Therapeutics Com New (ABEO) | 1.9 | $2.4M | +902% | 451k | 5.28 |
|
| Geron Corporation (GERN) | 1.8 | $2.2M | +60% | 1.6M | 1.37 |
|
| Pmv Pharmaceuticals (PMVP) | 1.6 | $1.9M | +61% | 1.4M | 1.40 |
|
| Edesa Biotech Com New (EDSA) | 1.4 | $1.7M | NEW | 688k | 2.47 |
|
| Aytu Biopharma (AYTU) | 1.4 | $1.7M | +9% | 892k | 1.88 |
|
| Soleno Therapeutics (SLNO) | 1.3 | $1.6M | NEW | 24k | 67.60 |
|
| Kezar Life Sciences Com New (KZR) | 1.2 | $1.5M | +125% | 383k | 3.90 |
|
| Alumis (ALMS) | 1.0 | $1.2M | -14% | 300k | 3.99 |
|
| Inhibikase Therapeutics Com New (IKT) | 1.0 | $1.2M | 735k | 1.62 |
|
|
| Bioage Labs (BIOA) | 0.9 | $1.1M | +24% | 189k | 5.88 |
|
| Ardelyx (ARDX) | 0.9 | $1.1M | -63% | 200k | 5.51 |
|
| Pulmonx Corp (LUNG) | 0.9 | $1.1M | +359% | 670k | 1.62 |
|
| Dynavax Technologies Corp Com New (DVAX) | 0.9 | $1.1M | +260% | 108k | 9.93 |
|
| Heron Therapeutics (HRTX) | 0.9 | $1.1M | +29% | 850k | 1.26 |
|
| Vanda Pharmaceuticals (VNDA) | 0.8 | $973k | -22% | 195k | 4.99 |
|
| Vir Biotechnology (VIR) | 0.7 | $914k | +23% | 160k | 5.71 |
|
| Mannkind Corp Com New (MNKD) | 0.7 | $846k | NEW | 158k | 5.37 |
|
| Maxcyte (MXCT) | 0.6 | $725k | NEW | 459k | 1.58 |
|
| An2 Therapeutics (ANTX) | 0.6 | $716k | +3% | 564k | 1.27 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.6 | $685k | +316% | 454k | 1.51 |
|
| AngioDynamics (ANGO) | 0.5 | $670k | -22% | 60k | 11.17 |
|
| Acasti Pharma (GRCE) | 0.5 | $628k | -27% | 211k | 2.98 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.5 | $602k | NEW | 20k | 30.08 |
|
| Syndax Pharmaceuticals (SNDX) | 0.5 | $572k | -59% | 37k | 15.38 |
|
| Aquestive Therapeutics (AQST) | 0.5 | $562k | NEW | 101k | 5.59 |
|
| Gossamer Bio (GOSS) | 0.4 | $539k | NEW | 205k | 2.63 |
|
| Boundless Bio (BOLD) | 0.4 | $509k | +289% | 414k | 1.23 |
|
| Health Catalyst (HCAT) | 0.4 | $443k | +55% | 156k | 2.85 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.4 | $434k | +51% | 11k | 40.99 |
|
| Pliant Therapeutics (PLRX) | 0.3 | $428k | NEW | 289k | 1.48 |
|
| Cytomx Therapeutics (CTMX) | 0.3 | $399k | NEW | 125k | 3.19 |
|
| Kiora Pharmaceuticals (KPRX) | 0.3 | $391k | -21% | 141k | 2.78 |
|
| Rezolute Com New (RZLT) | 0.3 | $376k | -81% | 40k | 9.40 |
|
| Aclaris Therapeutics (ACRS) | 0.3 | $367k | -60% | 193k | 1.90 |
|
| In8bio Com New (INAB) | 0.3 | $346k | +93% | 159k | 2.17 |
|
| Helius Med Technologies Com Cl A New (HSDT) | 0.2 | $298k | NEW | 20k | 14.89 |
|
| Codexis (CDXS) | 0.2 | $215k | NEW | 88k | 2.44 |
|
| Savara (SVRA) | 0.2 | $214k | -29% | 60k | 3.57 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.2 | $212k | NEW | 2.5k | 84.90 |
|
| Processa Pharmaceuticals Com Shs (PCSA) | 0.2 | $198k | NEW | 1.0M | 0.19 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $81k | NEW | 25k | 3.23 |
|
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.1 | $79k | NEW | 30k | 2.63 |
|
| Aadi Bioscience (WHWK) | 0.1 | $67k | NEW | 35k | 1.90 |
|
| Jasper Therapeutics Com New (JSPR) | 0.0 | $48k | NEW | 20k | 2.38 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2025 Q3 filed Nov. 13, 2025
- Stonepine Capital Management 2025 Q2 filed Aug. 13, 2025
- Stonepine Capital Management 2025 Q1 filed May 14, 2025
- Stonepine Capital Management 2024 Q4 filed Feb. 14, 2025
- Stonepine Capital Management 2024 Q3 filed Nov. 13, 2024
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022
- Stonepine Capital Management 2022 Q2 filed Aug. 12, 2022